Guardian Pharma

Origination strategy

We look for technology with real differentiation before the Brazilian market knows it.

Regulatory solutions

Regulatory classification and the viable pathway before ANVISA, defined before any commitment.

Commercial strategy

Research, price, channel and targets — the plan written before the first shipment.

Four regulated categories.

Every imported product starts with one decision: which regulatory regime it falls under. That is where we begin.

Cosmetics

Cosmetics, personal care products and fragrances, including high-technology dermocosmetics and professional-use actives.

Grade 1 and Grade 2 · notification and registration

Food

Foods, dietary supplements, ingredients and novel compounds — including those with no history of use in the country.

Registration, notification and assessment of novel ingredients

Medicines

Medicines, herbal medicines and active pharmaceutical ingredients, from the technical dossier to the licensing of the importing company.

Marketing authorization · AFE (company operating license) · import authorization

Medical devices

Medical devices and health products, from professional aesthetic devices to hospital lines.

Risk classes I to IV · notification and registration

An origination company

Most companies in this industry start by asking what is already ready to sell in Brazil. We start from the opposite question: what is the best the world has to offer that has not yet found its way here?

Origination, for us, means identifying the technology, the product and the manufacturer before the Brazilian market knows them — and taking on the regulatory work and the commercial design that separate a foreign innovation from an operation in Brazil.

That work has two inseparable fronts: the regulatory solution and the go-to-market strategy — which includes market research and the design of the distribution plan.

From the outside, Brazil looks impossible

ANVISA
AFE
Regulatory classification
Import
Labeling
Claims
Taxation
Legal representative
Sanitary responsibility

The list is long enough for good technologies to simply give up on the largest market in Latin America. For us, regulatory difficulty is not an obstacle to the business. It is the business.

The harder the entry, the more defensible the position of whoever got in first — and the more lasting the partnership built with the manufacturer.

Don't limit the analysis of your product for lack of regulation. That part is on us.

What we do

Regulatory

Technical product analysis, regulatory classification, claims assessment, dossier assembly, strategy before ANVISA and regularization.

Market research

Specialized research by category: market sizing, competition, price ranges, channel behavior and evaluation of players for representation.

Distribution plan

Definition of the complete chain — exporter, importer, distributor, professional channel and retail — with commercial policy, coverage and targets.

Channel assessment

Where the product wins: medical and professional channel, pharmacy, specialty retail and e-commerce — assessed and recommended, with candidate distributors mapped.

The whole chain, designed before the first order

Regulatory approval is not a sale. Between authorization and the consumer there is a chain that must be designed with data: who exports, who imports, who distributes, in which channel the product wins and at what price it sustains margin. That design is delivered as a plan, not as an opinion.

We call that document the Entry Route: your product's path from origin to the Brazilian shelf, written before the first shipment.

Manufacturer

R&D, formulation and production at origin.

Classification, regularization with ANVISA and the design of the chain.

Exporter

Supply terms, incoterms, documentation and volumes.

Distributor

Regional coverage, inventory, commercial policy and targets.

Channel

Clinics, practices, pharmacies and specialty retail.

Consumer

Demand built with brand, evidence and recommendation.

What the Entry Route answers

Category size and growth, direct competitors and substitutes, price ranges in practice, seasonality and segment-specific entry barriers.

What the Entry Route defines

Entry model, price structure from factory to consumer, selection and evaluation of distributors, coverage by region, sell-in and sell-out targets and marketing investment.

How we work

01Origination

We map technologies, manufacturers and portfolios with real differentiation, prioritizing high added value that has no representation in Brazil yet.

02Technical and regulatory analysis

We receive the technical dossier, composition, claims and certificates. We define the classification and the viable regulatory pathway before any commercial commitment.

03Research and distribution plan

Market research for the category, chain design, selection of distributors and channels, price structure and targets by region.

04Regularization and delivery of the plan

We carry the regularization with ANVISA through to approval and hand over the distribution plan ready to be executed — by you or by the partner you choose.

Few technologies. Hard to replace.

We are not after an extensive catalog of imported brands. We are after a small number of high-value technologies, each with the right channel identified before entry.

Dermocosmetics

Highly differentiated actives with provable technical appeal.

Professional channel

Clinics, practices and aesthetic and healthcare services.

Premium consumer

Pharmacy, specialty retail and brand e-commerce.

Concentration builds depth. Depth creates a category.

Who we work for

Manufacturers with no representation in Brazil

The technology is ready abroad and there is no path into the country. This is the most common case: the product exists, the market exists, and what is missing is someone to take on the journey between the two.

Those who tried and stalled at the regulatory stage

A dossier assembled for another country, a claim that does not hold up before ANVISA, a classification defined wrongly at the start. We pick up from where it stalled instead of starting over.

Brands whose registration is held by their distributor

Whoever holds the registration controls market access. When the partnership stops working, changing distributor can mean redoing the regularization. We assess your situation before proposing any move.

Why Guardian Pharma

ANVISA is in Brasília. So are we.

We are in the same city as the agency that decides your product's classification. It is not a shortcut — there are no regulatory shortcuts — but it shortens the distance between a published requirement and the answer that clears it.

Origination, not a catalogue

We do not represent whatever is already knocking at the door. We look for technology with real differentiation before the Brazilian market knows it, and we solve what blocks its entry: the regulatory classification and the design of the chain.

Four categories under one roof

Cosmetics, food, medicines and medical devices. An imported portfolio rarely fits into a single category, and each one has its own regulatory regime — handling all four in one place keeps a product from stalling on the border between them.

The plan comes before the shipment

The Entry Route is delivered as a document: category research, price structure from factory to consumer, channel selection and targets by region. You decide with data on the table, not after the first container is already sitting still.

Questions from the other side

Do we need to open a company in Brazil?

No. ANVISA does not accept a registration held by a foreign company: regularization is done by a Brazilian company holding an operating authorization (AFE), which carries sanitary responsibility for the product in the country. That is the position Guardian Pharma occupies. Your team stays on research, formulation and manufacturing.

Who holds the marketing authorization?

The authorization is issued in the name of the Brazilian company that answers for it. That is why ownership and transfer conditions are defined in the agreement before any submission — it is the clause that decides your negotiating power later on, and we deal with it at the start, not at the end.

Do you assess the product before there is a commercial agreement?

Yes. We receive the technical dossier, composition, claims and certificates, and we define the regulatory classification and the viable pathway before any commercial commitment. The material is treated as confidential and is not shared with third parties without your authorization.

How long until the product can be sold?

It depends on the classification — which is precisely why the classification comes first. Lower-risk products follow the notification route, which is considerably faster; registration requires a complete technical dossier and ANVISA review. We would rather give you a timeline after looking at your product than repeat an average that does not apply to your case.

My ingredient has no history of use in Brazil. Does that rule it out?

Not necessarily. Ingredients and compounds with no history of consumption in the country have their own assessment pathway: longer and more document-heavy, but it exists. Don't limit the analysis of your product for lack of regulation — that part is on us.

After approval, who sells?

You do, or the distributor you choose. Regulatory approval is not a sale, and we do not run the commercial operation: we deliver the distribution plan — exporter, importer, distributor, professional channel and retail, with commercial policy, coverage and targets — designed with market research, and we support the selection of the partner who will execute it.

For the press

Guardian Pharma is a Brazilian origination and market-entry company based in Brasília. It handles the regulatory solution and the go-to-market strategy for imported products in the cosmetics, food, medicines and medical devices categories — from regulatory classification with ANVISA to market research and distribution planning.

Headquarters: Brasília, DF — Brazil
Founded: 2026
Categories: Cosmetics, food, medicines, medical devices
Source markets: Asia, Europe and North America
Legal entity: GUARDIAN TEC TECNOLOGIA LTDA · CNPJ 40.351.607/0001-30
Press contact: guardianpharmadf@gmail.com

You develop. We solve Brazil.

Your company keeps doing what it does best: research, formulation, manufacturing and innovation. Guardian Pharma solves the regulatory path and designs the route to the Brazilian consumer — with the distribution plan ready before the first shipment.

Schedule a conversation Send a technical dossier

We originate what hasn't reached Brazil yet.